🇺🇸 $JNJ: #Tremfya sold $2.4bn in Q3, up 68%, while #Stelara fell 54% to $0.7bn under biosimilar competition.
Tremfya overtook it in Q4 2025, and J&J's immunology sales overall still grew 1.3%.

Long-Term Efficacy of TREMFYA® in Treating Crohn's Disease Highlighted by New Study Results #USA #Spring_House #Crohn's_Disease #TREMFYA #guselkumab
New Study Reveals TREMFYA® Effectively Treats Perianal Fistulas in Crohn's Disease Patients #United_States #Spring_House #Crohn's_Disease #TREMFYA #guselkumab
TREMFYA® Breakthrough: First IL-23 Inhibitor to Alleviate Spinal Pain in Psoriatic Arthritis #USA #Spring_House #TREMFYA #guselkumab #Psoriatic_Arthritis